Skip to main content
All lobbying filings

FAMILIES USA FOUNDATION, INC.

Lobbying for FAMILIES USA FOUNDATION INC

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $6,000.00 expenses · posted Jan 27, 2026

Official filing document

 Bills named in this filing 1
  • HR 247
    Health Care Affordability Act of 2025
 Lobbying activity 3
Medicare/Medicaid

S.1105No UPCODE ActA bill to amend title XVIII of the Social Security Act to improve risk adjustment under Medicare Advantage. H.R.6148Patients Over Paperwork Act of 2025To amend public law to repeal certain changes to eligibility redeterminations under the Medicaid program. TBDTBDTo amend title XI of the Social Security Act to establish a Federal loan program to support the provision of pregnancy-related services, and for other purposes. TBDTBDTo amend title XIX of the Social Security Act to establish an optional cost-sharing agreement program between State Medicaid programs and the Centers for Medicare & Medicaid Services to increase Medicaid reimbursement rates for pregnancy-related services, and for other purposes. Legislation to advance site neutral payment reforms S.2497Fair Billing ActLegislation to ensure fair billing practice for items and services furnished by off-campus hospital locations a bill to task the Centers for Medicare & Medicaid Services (CMS) with establishing hybrid payments to reward primary care providers who provide the best care to their patients S. 2355Patients Deserve Price Tags ActLegislation to strengthen and codify federal hospital and insurer transparency rules to ensure the publication of prices in dollars and cents

Pharmacy

S.527Prescription Pricing for the People Act of 2025To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes. S.1040Drug Competition Enhancement ActTo amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. S.1041Affordable Prescriptions for Patients ActTo amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1097Interagency Patent Coordination and Improvement Act of 2025To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. S.1095Stop STALLING ActTo enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. S.1096Preserve Access to Affordable Generics and BiosimilarsTo prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products

Health Issues

H.R.247/S.46Health Care Affordability ActTo amend the Internal Revenue Code of 1986 to expand eligibility for the refundable credit for coverage under a qualified health plan. S.J.Res.82Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Office of the Secretary of the Department of Health and Human Services relating to Policy on Adhering to the Text of the Administrative Procedure Act.Richardson Waiver Healthy Competition for Better Care Actlegislation to ban anticompetitive terms in insurer-provider contracts

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem